AGÕæÈ˹ٷ½

STOCK TITAN

[8-K] Hoth Therapeutics, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Hoth Therapeutics has filed an 8-K report announcing the preparation of new presentation materials that management plans to use for company presentations starting June 24, 2025. The materials are included as Exhibit 99.1 to the Current Report.

Key points from the filing:

  • The presentation materials contain summary information that should be considered alongside the company's SEC filings and other public announcements
  • The company maintains discretion to update the materials but has no obligation to do so
  • Information provided under Item 7.01 and Exhibit 99.1 is furnished rather than "filed" under SEC regulations
  • The information will not be incorporated by reference into any Securities Act or Exchange Act filings

The filing was signed by CEO Robb Knie and includes the standard Cover Page Interactive Data File in Inline XBRL format.

Hoth Therapeutics ha presentato un rapporto 8-K annunciando la preparazione di nuovi materiali per presentazioni che la direzione intende utilizzare a partire dal 24 giugno 2025. I materiali sono inclusi come Allegato 99.1 al Rapporto Corrente.

Punti chiave del documento:

  • I materiali della presentazione contengono informazioni riassuntive che devono essere considerate insieme ai documenti SEC della società e ad altri annunci pubblici
  • La società si riserva la facoltà di aggiornare i materiali, ma non è obbligata a farlo
  • Le informazioni fornite ai sensi del Punto 7.01 e dell'Allegato 99.1 sono fornite e non "depositate" secondo le normative SEC
  • Le informazioni non saranno incorporate per riferimento in nessun deposito ai sensi del Securities Act o dell'Exchange Act

Il documento è stato firmato dal CEO Robb Knie e include la consueta Pagina di Copertina con il File Dati Interattivo in formato Inline XBRL.

Hoth Therapeutics ha presentado un informe 8-K anunciando la preparación de nuevos materiales de presentación que la dirección planea usar para presentaciones de la empresa a partir del 24 de junio de 2025. Los materiales están incluidos como Anexo 99.1 en el Informe Actual.

Puntos clave del informe:

  • Los materiales de presentación contienen información resumida que debe considerarse junto con los documentos de la SEC y otros anuncios públicos de la empresa
  • La empresa se reserva la discreción de actualizar los materiales, pero no tiene obligación de hacerlo
  • La información proporcionada bajo el Punto 7.01 y el Anexo 99.1 se suministra y no se "presenta" según las regulaciones de la SEC
  • La información no se incorporará por referencia en ningún archivo bajo la Ley de Valores o la Ley de Intercambio

El informe fue firmado por el CEO Robb Knie e incluye la Página de Portada estándar con el Archivo de Datos Interactivos en formato Inline XBRL.

Hoth TherapeuticsëŠ� 2025ë…� 6ì›� 24ì¼ë¶€í„� 회사 프레젠테ì´ì…˜ì—� 사용í•� 새로ìš� 발표 ìžë£Œë¥� 준ë¹� 중임ì� 알리ëŠ� 8-K 보고서를 제출했습니다. ì� ìžë£ŒëŠ� 현재 ë³´ê³ ì„œì˜ ì²¨ë¶€ë¬¸ì„œ 99.1ì—� í¬í•¨ë˜ì–´ 있습니다.

보고� 주요 내용:

  • 발표 ìžë£ŒëŠ� 회사ì� SEC 제출 문서 ë°� 기타 공개 발표와 함께 고려해야 하는 요약 ì •ë³´ë¥� í¬í•¨í•˜ê³  있습니다
  • 회사ëŠ� ìžë£Œë¥� ì—…ë°ì´íЏí•� 재량ì� 있으ë‚�, 반드ì‹� 해야 í•� ì˜ë¬´ëŠ� 없습니다
  • 항목 7.01 ë°� 첨부문서 99.1ì—� 제공ë� ì •ë³´ëŠ� SEC 규정ì—� ë”°ë¼ '제출'ë� ê²ƒì´ ì•„ë‹ˆë� '제공'ë� 것입니다
  • 해당 ì •ë³´ëŠ� ì¦ê¶Œë²� ë˜ëŠ” 거래ë²� ê´€ë � 제출 문서ì—� 참조ë¡� í¬í•¨ë˜ì§€ 않습니다

ì� 보고서는 CEO Robb Knieê°€ 서명했으ë©�, 표준 커버 페ì´ì§€ 대화형 ë°ì´í„� 파ì¼ì� Inline XBRL 형ì‹ìœ¼ë¡œ í¬í•¨í•˜ê³  있습니다.

Hoth Therapeutics a déposé un rapport 8-K annonçant la préparation de nouveaux supports de présentation que la direction prévoit d'utiliser pour les présentations de l'entreprise à partir du 24 juin 2025. Les supports sont inclus en tant que Pièce 99.1 dans le rapport actuel.

Points clés du dépôt :

  • Les supports de présentation contiennent des informations résumées qui doivent être considérées en complément des dépôts SEC de la société et d'autres annonces publiques
  • La société se réserve le droit de mettre à jour les supports, sans y être obligée
  • Les informations fournies conformément à l'Article 7.01 et à la Pièce 99.1 sont fournies et non « déposées » selon la réglementation SEC
  • Ces informations ne seront pas incorporées par référence dans des dépôts au titre du Securities Act ou de l'Exchange Act

Le dépôt a été signé par le CEO Robb Knie et comprend la page de couverture standard avec le fichier de données interactives au format Inline XBRL.

Hoth Therapeutics hat einen 8-K-Bericht eingereicht, in dem die Vorbereitung neuer Präsentationsmaterialien angekündigt wird, die das Management ab dem 24. Juni 2025 für Unternehmenspräsentationen verwenden möchte. Die Materialien sind als Anlage 99.1 zum aktuellen Bericht beigefügt.

Wichtige Punkte aus der Einreichung:

  • Die Präsentationsmaterialien enthalten zusammenfassende Informationen, die zusammen mit den SEC-Einreichungen des Unternehmens und anderen öffentlichen Bekanntmachungen betrachtet werden sollten
  • Das Unternehmen behält sich das Recht vor, die Materialien zu aktualisieren, ist dazu jedoch nicht verpflichtet
  • Die unter Punkt 7.01 und Anlage 99.1 bereitgestellten Informationen werden gemäß SEC-Vorschriften bereitgestellt und nicht "eingereicht"
  • Die Informationen werden nicht durch Verweis in Wertpapier- oder Börsengesetz-Einreichungen aufgenommen

Die Einreichung wurde vom CEO Robb Knie unterzeichnet und enthält die standardmäßige Deckblatt-Interaktive Daten-Datei im Inline-XBRL-Format.

Positive
  • None.
Negative
  • None.

Hoth Therapeutics ha presentato un rapporto 8-K annunciando la preparazione di nuovi materiali per presentazioni che la direzione intende utilizzare a partire dal 24 giugno 2025. I materiali sono inclusi come Allegato 99.1 al Rapporto Corrente.

Punti chiave del documento:

  • I materiali della presentazione contengono informazioni riassuntive che devono essere considerate insieme ai documenti SEC della società e ad altri annunci pubblici
  • La società si riserva la facoltà di aggiornare i materiali, ma non è obbligata a farlo
  • Le informazioni fornite ai sensi del Punto 7.01 e dell'Allegato 99.1 sono fornite e non "depositate" secondo le normative SEC
  • Le informazioni non saranno incorporate per riferimento in nessun deposito ai sensi del Securities Act o dell'Exchange Act

Il documento è stato firmato dal CEO Robb Knie e include la consueta Pagina di Copertina con il File Dati Interattivo in formato Inline XBRL.

Hoth Therapeutics ha presentado un informe 8-K anunciando la preparación de nuevos materiales de presentación que la dirección planea usar para presentaciones de la empresa a partir del 24 de junio de 2025. Los materiales están incluidos como Anexo 99.1 en el Informe Actual.

Puntos clave del informe:

  • Los materiales de presentación contienen información resumida que debe considerarse junto con los documentos de la SEC y otros anuncios públicos de la empresa
  • La empresa se reserva la discreción de actualizar los materiales, pero no tiene obligación de hacerlo
  • La información proporcionada bajo el Punto 7.01 y el Anexo 99.1 se suministra y no se "presenta" según las regulaciones de la SEC
  • La información no se incorporará por referencia en ningún archivo bajo la Ley de Valores o la Ley de Intercambio

El informe fue firmado por el CEO Robb Knie e incluye la Página de Portada estándar con el Archivo de Datos Interactivos en formato Inline XBRL.

Hoth TherapeuticsëŠ� 2025ë…� 6ì›� 24ì¼ë¶€í„� 회사 프레젠테ì´ì…˜ì—� 사용í•� 새로ìš� 발표 ìžë£Œë¥� 준ë¹� 중임ì� 알리ëŠ� 8-K 보고서를 제출했습니다. ì� ìžë£ŒëŠ� 현재 ë³´ê³ ì„œì˜ ì²¨ë¶€ë¬¸ì„œ 99.1ì—� í¬í•¨ë˜ì–´ 있습니다.

보고� 주요 내용:

  • 발표 ìžë£ŒëŠ� 회사ì� SEC 제출 문서 ë°� 기타 공개 발표와 함께 고려해야 하는 요약 ì •ë³´ë¥� í¬í•¨í•˜ê³  있습니다
  • 회사ëŠ� ìžë£Œë¥� ì—…ë°ì´íЏí•� 재량ì� 있으ë‚�, 반드ì‹� 해야 í•� ì˜ë¬´ëŠ� 없습니다
  • 항목 7.01 ë°� 첨부문서 99.1ì—� 제공ë� ì •ë³´ëŠ� SEC 규정ì—� ë”°ë¼ '제출'ë� ê²ƒì´ ì•„ë‹ˆë� '제공'ë� 것입니다
  • 해당 ì •ë³´ëŠ� ì¦ê¶Œë²� ë˜ëŠ” 거래ë²� ê´€ë � 제출 문서ì—� 참조ë¡� í¬í•¨ë˜ì§€ 않습니다

ì� 보고서는 CEO Robb Knieê°€ 서명했으ë©�, 표준 커버 페ì´ì§€ 대화형 ë°ì´í„� 파ì¼ì� Inline XBRL 형ì‹ìœ¼ë¡œ í¬í•¨í•˜ê³  있습니다.

Hoth Therapeutics a déposé un rapport 8-K annonçant la préparation de nouveaux supports de présentation que la direction prévoit d'utiliser pour les présentations de l'entreprise à partir du 24 juin 2025. Les supports sont inclus en tant que Pièce 99.1 dans le rapport actuel.

Points clés du dépôt :

  • Les supports de présentation contiennent des informations résumées qui doivent être considérées en complément des dépôts SEC de la société et d'autres annonces publiques
  • La société se réserve le droit de mettre à jour les supports, sans y être obligée
  • Les informations fournies conformément à l'Article 7.01 et à la Pièce 99.1 sont fournies et non « déposées » selon la réglementation SEC
  • Ces informations ne seront pas incorporées par référence dans des dépôts au titre du Securities Act ou de l'Exchange Act

Le dépôt a été signé par le CEO Robb Knie et comprend la page de couverture standard avec le fichier de données interactives au format Inline XBRL.

Hoth Therapeutics hat einen 8-K-Bericht eingereicht, in dem die Vorbereitung neuer Präsentationsmaterialien angekündigt wird, die das Management ab dem 24. Juni 2025 für Unternehmenspräsentationen verwenden möchte. Die Materialien sind als Anlage 99.1 zum aktuellen Bericht beigefügt.

Wichtige Punkte aus der Einreichung:

  • Die Präsentationsmaterialien enthalten zusammenfassende Informationen, die zusammen mit den SEC-Einreichungen des Unternehmens und anderen öffentlichen Bekanntmachungen betrachtet werden sollten
  • Das Unternehmen behält sich das Recht vor, die Materialien zu aktualisieren, ist dazu jedoch nicht verpflichtet
  • Die unter Punkt 7.01 und Anlage 99.1 bereitgestellten Informationen werden gemäß SEC-Vorschriften bereitgestellt und nicht "eingereicht"
  • Die Informationen werden nicht durch Verweis in Wertpapier- oder Börsengesetz-Einreichungen aufgenommen

Die Einreichung wurde vom CEO Robb Knie unterzeichnet und enthält die standardmäßige Deckblatt-Interaktive Daten-Datei im Inline-XBRL-Format.

false 0001711786 0001711786 2025-06-24 2025-06-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) June 24, 2025

 

Hoth Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

Nevada   001-38803   82-1553794
(State or other jurisdiction
of incorporation)
  (Commission File Number)   (I. R. S. Employer
Identification No.)

 

1177 Avenue of the Americas, 5th Floor, Suite 066

New York, NY 10036

(Address of principal executive offices, including ZIP code)

 

(646756-2997

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common stock, $0.0001 par value   HOTH   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

 

 

 

 

 

 

Item 7.01. Regulation FD Disclosure.

 

Hoth Therapeutics, Inc. (the “Company”) has prepared presentation materials (the “Presentation Materials”) that management intends to use from time to time on and after June 24, 2025 in presentations about the Company’s business. The Presentation Materials are furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information contained in the Presentation Materials is summary information that should be considered within the context of the Company’s filings with the Securities and Exchange Commission and other public announcements that the Company may make by press release or otherwise from time to time. The Presentation Materials speak as of the date of this Current Report on Form 8-K. While the Company may elect to update the Presentation Materials in the future or reflect events and circumstances occurring or existing after the date of this Current Report on Form 8-K, the Company specifically disclaims any obligation to do so.

 

The information in this Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K is furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information in this Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report on Form 8-K, regardless of any general incorporation language in any such filing.

 

Item 9.01. Financial Statements and Exhibits.

 

d) Exhibits

 

Exhibit No.   Description
99.1   Presentation Materials dated June 2025
104   Cover Page Interactive Data File (formatted as Inline XBRL)

 

-1-

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: June 24, 2025 Hoth Therapeutics, Inc.
   
  /s/ Robb Knie
  Robb Knie
  Chief Executive Officer

 

 

-2-

 

 

FAQ

What did HOTH announce in their 8-K filing on June 24, 2025?

HOTH announced the preparation of new presentation materials that management plans to use from time to time starting June 24, 2025, to present information about the company's business. These presentation materials were furnished as Exhibit 99.1 to the Current Report.

Who signed HOTH's June 24, 2025 8-K filing?

The 8-K was signed by Robb Knie, Chief Executive Officer of Hoth Therapeutics, Inc.

What exhibits were included in HOTH's June 2025 8-K filing?

The filing included two exhibits: Exhibit 99.1 (Presentation Materials dated June 2025) and Exhibit 104 (Cover Page Interactive Data File formatted as Inline XBRL).

Is HOTH required to update the presentation materials disclosed in the June 2025 8-K?

No, while HOTH may elect to update the presentation materials in the future, the company specifically disclaims any obligation to do so. The materials speak as of the date of the Current Report.

Will HOTH's presentation materials be considered 'filed' under SEC regulations?

No, the information in Item 7.01 and Exhibit 99.1 is explicitly stated to be 'furnished' and not 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, and will not be incorporated by reference into any future SEC filings.
Hoth Therapeutics Inc

NASDAQ:HOTH

HOTH Rankings

HOTH Latest News

HOTH Latest SEC Filings

HOTH Stock Data

17.77M
12.70M
0.5%
1.98%
2.31%
Biotechnology
Pharmaceutical Preparations
United States
NEW YORK